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ARTICLECoagulation & Its Disorders
doi:10.3324/haematol.2015.136275
The role of pharmacokinetic-guided dosing of factor concentratesin hemophilia is currently a subject of debate and focuses on long-term prophylactic treatment. Few data are available on its impact
in the perioperative period. In this study, a population pharmacokinetic
model for currently registered factor VIII concentrates was developed
for severe and moderate adult and pediatric hemophilia A patients (FVIII
levels <0.05 IUmL-1) undergoing elective, minor or major surgery.
Retrospective data were collected on FVIII treatment, including timing
and dosing, time point of FVIII sampling and all FVIII plasma concentra-
tions achieved (trough, peak and steady state), brand of concentrate, as
well as patients' and surgical characteristics. Population pharmacokinet-
ic modeling was performed using non-linear mixed-effects modeling.
Population pharmacokinetic parameters were estimated in 75 adults
undergoing 140 surgeries (median age: 48 years; median weight: 80 kg)
and 44 children undergoing 58 surgeries (median age: 4.3 years; median
weight: 18.5 kg). Pharmacokinetic profiles were best described by a
two-compartment model. Typical values for clearance, inter-compart-
ment clearance, central and peripheral volume were 0.15 L/h/68 kg, 0.16
L/h/68 kg, 2.81 L/68 kg and 1.90 L/68 kg. Interpatient variability in clear-
ance and central volume was 37% and 27%. Clearance decreased with
increasing age (P<0.01) and increased in cases with blood group O
(26%; P<0.01). In addition, a minor decrease in clearance was observed
when a major surgical procedure was performed (7%; P<0.01). The
developed population model describes the perioperative pharmacoki-
netics of various FVIII concentrates, allowing individualization of peri-
operative FVIII therapy for severe and moderate hemophilia A patients
by Bayesian adaptive dosing.
ABSTRACT
Introduction
Hemophilia A is an X-linked hereditary bleeding disor-
der characterized by a deficiency of coagulation factor VIII
(FVIII). Current management of hemophilia patients con-
sists of replacement therapy with plasma derived or
recombinant factor concentrates in case of acute bleeding
(“on demand”) or to prevent spontaneous or perioperative
bleeding (“prophylaxis”). The aim of long-term prophylac-
tic treatment is to prevent severe joint damage and subse-
quent long-term invalidity by raising FVIII trough plasma
concentrations to at least 0.01 IUml-1.1,2 To acquire ade-
quate hemostasis in the surgical setting, normalization of
coagulation factor levels is advocated for 7-14 days after
surgery in most perioperative protocols.3
Treatment with factor concentrates is costly. In the
Netherlands, total annual costs of replacement therapy are
estimated at more than 130 million euro and include costs
for prophylactic and “on demand” treatment.4-7 In the
Canadian Hemophilia Registry, perioperative consump-
tion amounts to 1%-3% of the total annual amount
administered.8
As we have reported earlier, coagulation factor plasma
concentrations as recommended by National and
International Guidelines are often exceeded in the periop-
erative setting to avoid lower plasma concentrations and a
possibly higher bleeding risk, with additional costs.9,10 In a
retrospective analysis of hemophilia A patients undergo-
ing surgery, 45% of FVIII plasma concentrations were
below the target range during the first 24 hours after sur-
gery and 75% of the plasma concentration were above the
target range after six days of hospitalization. In addition, a
reduction of 44% in factor concentrates could have been
reached if plasma concentrations had been maintained
within target levels in the perioperative setting.9 
In the prophylactic setting, Carlsson et al. have shown
that FVIII consumption can be significantly reduced by
application of pharmacokinetic (PK) modeling to individu-
alize dosing regimens.11-14 In the perioperative setting,
Longo et al. have reported excessive FVIII consumption
and clearance in 50% of surgical hemophilia patients due
to unidentified factors.15 This suggests mechanisms of
increased clearance due to hemostatic challenges during
surgery. Although an initial preoperative factor concen-
trate bolus dose may be individualized by individual PK
parameters obtained after an individual PK profile based
on a prophylactic population PK model, this may not be
applicable as soon as a surgical procedure is initiated. A
perioperative population PK model, however, would
make PK-guided iterative adaptive Bayesian dosing with a
potential concomitant decrease of factor concentrate con-
sumption possible. During this procedure individual PK
parameters are iteratively up-dated by combining PK
information (e.g. dose, concentration, time) from the indi-
vidual patient with a priori PK information (e.g. average
clearance, variability) from the population. But this infor-
mation is not currently available and has, therefore, never
been performed. 
In order to construct a perioperative population PK
model of this kind, to facilitate Bayesian adaptive dosing
in severe and moderate hemophilia A, we collected
detailed retrospective FVIII infusion data in patients who
had undergone surgery under replacement therapy with
various similar FVIII concentrates from five hemophilia
treatment centers. 
Methods
Patients’ characteristics and data collection 
Severe and moderate hemophilia A patients of all ages with
FVIII plasma concentration less than 0.05 IUml-1 who had under-
gone elective, minor or major surgical procedures between 2000
and 2013 from five Academic Hemophilia Treatment Centers in
the Netherlands were included.9 Patients received replacement
therapy consisting of various recombinant factor concentrates
(Kogenate FS: Bayer, Berkely, Ca, USA; Helixate FS: CSL Behring,
Marburg, Germany; Advate and Recombinate: Baxter Bioscience,
Thousand Oaks, CA, USA; Refacto AF: Pfizer, New York, NY
USA) or plasma derived factor concentrates (Aafact: Blood
Transfusion council of the Netherlands Red Cross; Hemofil M:
Baxter Bioscience, Thousand Oaks, CA, USA) to achieve target
FVIII plasma concentrations as set by the National Hemophilia
Consensus. This guideline recommends peak and trough FVIII
plasma concentrations on consecutive postoperative days (Table
1): 0-24 hours 0.80-1.00 IUml-1; 24-120 hours 0.50-0.80 IUml-1 and
more than 120 hours 0.30-0.50 IUml-1.3 The following retrospec-
tive data were collected: FVIII dosages, detailed timing of admin-
istration and timing of FVIII blood sampling, mode of infusion
(continuous or bolus infusion), all achieved FVIII plasma concen-
trations (both trough, peak and steady state plasma concentra-
tions), patients' and surgical characteristics, and concomitant med-
ication with a possible effect on hemostasis (i.e. tranexamic acid,
heparin, desmopressin and non-steroidal anti-inflammatory
drugs). Patients' characteristics included: body weight, length, lean
body mass,16,17 body mass index (BMI),18 blood group, von
Willebrand Factor (VWF) antigen and VWF activity (historically
measured), liver and renal function, clinical bleeding phenotype,
history of FVIII inhibiting antibodies, intensity of prophylactic
dosing regimen, brand of concentrate, and treatment center.
Surgical characteristics included type and severity of surgical pro-
cedure categorized into minor, major and high risk according to
Koshy et al.19 In all centers, FVIII plasma concentrations were
measured by one-stage clotting assays. The study was not subject
to the conditions of the Medical Research Involving Human
Subjects Act, as patient data were analyzed anonymously. The
study was approved by all local Medical Ethics Committees; one
center required prior patient informed consent. 
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Table 1. Prevalence of under- and overdosing in the perioperative period.*
Time (hours) 0-24 24-120 >120
Consensus 0.80-1.00 IUml-1 0.50-0.80 IUml-1 0.30-0.50 IUml-1
% above 33% (>1.00 IUml-1) 59% (>0.80 IUml-1) 75% (>0.50 IUml-1)
% below 45% (<0.80 IUml-1) 7% (<0.50 IUml-1) 9% (<0.30 IUml-1)  
*According to the National Hemophilia Consensus.
Pharmacokinetic modeling
Population PK is defined as the study of sources of variability in
drug concentrations after dosing that occurs both in individual
patients and between patients.20 In the present population analy-
sis, all plasma concentration time points were analyzed simultane-
ously using non-linear mixed-effects modeling software (NON-
MEM v.7.2.0; Globomax LLC, Ellicott City, Maryland, USA).21 All
PK-related abbreviations and terminology are described in Online
A perioperative population pharmacokinetic model 
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Table 2. Characteristics of the study population.
Patients' characteristics Total cohort Adults Children
N. (%); or median 
[minimum; maximum]
N. of patients 119 75 44
Age (years) 40 [0.2-78] 48 [19-78] 4 [0.2-17.3]
Weight (kg) 75 [5-111] 80 [45-111] 19 [5-85]
Severe hemophilia 
(FVIII levels <0.01 IUml-1) 83 (69.7) 49 (65.3) 34 (77.3)
On prophylaxis 84 (70.6) 51 (68.0) 33 (75.0)
Blood group O* 51 (50.5) 34 (50.0) 17 (51.5)
Historical VWF levels (mmoll) 
Antigen 1.1 [0.3-2.5] 1.2 [0.3-2.5] 0.9 [0.5-2.3]
Activity 1.1 [0.2-2.7] 1.4 [0.2-2.7] 0.9 [0.4-1.7]
Surgical characteristics
Total n. of surgical procedures 198 140 58
N. of patients undergoing:
1 procedure 75 (63.0) 43 (57.3) 32 (72.7)
2 procedures 26 (21.8) 15 (20.0) 11 (25.0)
3 procedures 9 (7.6) 9 (12.0) 0 (0.0)
>4 procedures 9 (7.6) 8 (10.7) 1 (2.3)
Major surgical procedure 97 (49.0) 86 (61.4) 11 (19.0)
Type of surgical procedure
General 6 (3.0) 6 (4.3) 0 0
Colo-rectal 5 (2.5) 4 (2.9) 1 (1.7)
Vascular 1 (0.5) 1 (0.7) 0 0
Cardio-thoracic 1 (0.5) 1 (0.7) 0 0
Orthopedic 94 (47.5) 91 (65.0) 3 (5.2)
Urology 12 (6.1) 4 (2.9) 8 (13.8)
Maxillofacial 2 (1.0) 2 (1.4) 0 0
Ear-nose-throat 11 (5.6) 6 (4.3) 5 (8.6)
Eye 3 (1.5) 3 (2.1) 0 0
(Re)placement of central 32 (16.2) 1 (0.7) 31 (53.4)
intravenous catheters
Miscellaneous 31 (15.7) 21 (15.0) 10 (17.2)
Replacement therapy with factor concentrate, hospitalization and blood loss
Mode of infusion
Continuous 115 (58.1) 88 (62.9) 27 (46.6)
Bolus 83 (41.9) 52 (37.1) 31 (53.4)
Product type
Recombinant 152 (76.8) 99 (70.7) 53 (91.4)
Plasma derived 46 (23.2) 41 (29.3) 5 (8.6)
Duration of hospitalization (days) 9 [1-50] 9 [1-50] 7 [1-16]
Complications during the perioperative period
N. of patients with a complication
Bleeding 48 (24.2) 45 (32.1) 3 (5.2)
Re-operation 6 (3.0) 6 (4.3) 0 0
Hemoglobin drop >20 gL-1 38 (19.2) 36 (25.7) 2 (3.4)
and/or erythrocyte transfusion
Bleeding with prolonged hospitalization 5 (2.5) 4 (2.9) 1 (1.7)
Thrombosis 0 0 0 0 0 0
FVIII data 
FVIII measurements (trough, peak and SS) 1389 1124 265
Prior to surgery 158 (11.4) 114 (10.1) 44 (16.6)
Day 1 (0 - 24 hours) 323 (23.2) 246 (21.9) 76 (28.7)
Day 2 - 5 (24 - 120 hours) 473 (34.0) 363 (32.3) 110 (41.5)
Day > 6 (>120 hours) 436 (31.4) 401 (35.7) 35 (13.2)
N.: number; %:  percentages; kg: kilogram; FVIII: coagulation factor VIII; IUml-1: international units per milliliter; BU: Bethesda Units;  VWF: von Willebrand factor; mmoll-1: millimolar
per liter; gL-1: gram per liter; SS: steady state; *blood group known for 101 patients. 
Supplementary Table S1. More specifically, first-order conditional
estimation (FOCE) method with interaction was applied, allowing
interaction between structural and residual variance components.
The statistical package R v.2.14.2 (The R Foundation for Statistical
Computing) and Xpose version 422 were used for data set check-
out, exploration and model diagnostics. Pirana software was used
as an interface between NONMEM, R and Xpose.23 
Model diagnostics included the evaluation of the goodness of fit
plots, the objective function value (OFV), the precision of the
parameter estimates and the shrinkage of estimated random
parameters. The OFV is a measurement of goodness of fit of the
model and is proportional to minus two times the logarithm of the
likelihood (-2log likelihood) of the data. Competing hierarchical
models were compared by calculating the difference between
their OFV. This ratio is assumed to be χ2 distributed. Therefore, if
models differ by one parameter, a decrease in OFV of 3.84 corre-
sponds to P=0.05 (1 degree of freedom) and OFV decreases of 6.63
and 10.8 correspond to P=0.01 and 0.001, respectively. 
Structural model development 
FVIII plasma concentrations were described by a two-compart-
ment PK model. Estimated (fixed) parameters were clearance (CL),
volume of distribution of the central compartment (V1), inter-
compartment clearance (Q), and volume of distribution of the
peripheral compartment (V2). The structural model also accounted
for the individual endogenous baseline FVIII plasma concentra-
tion. PK parameters were allometrically scaled to account for the
wide range of body weights of both adult and pediatric patients.
An allometric power model was used with power exponents fixed
at 0.75 for clearances and 1.0 for volumes of distribution,24 as
described in the following equations: 
 CLi = θCL×(BWi /68)
0.75
VLi=θV1×(BWi /68)
In this expression, CLi and Vi are the typical clearance and cen-
tral volume of distribution for an individual i with body weight
BWi while θCL and θV1 are the respective parameter values for a
subject with a body weight of 68 kilogram. 
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Figure 1. Perioperative FVIII plasma concentrations and visual predictive check for observed FVIII plasma concentrations. Perioperative FVIII plasma concentrations
consist of trough, peak and steady state concentrations for both modes of therapy (continuous infusion and bolus infusion therapy). Visual predictive check for the
observed FVIII plasma concentrations, given the final model. Observed FVIII plasma concentrations and mean, 5th percentile and 95th percentile observed and sim-
ulated FVIII plasma concentrations. 
Table 3. Model-building steps resulting in significant decreases in objective function value (OFV).
Model NOP OFV
Structural model*
1 One compartment with IIV on V1 and CL 7 -2604.5
2 Two compartments with IIV on V1 and CL 9 -2799.3
3 Inclusion of individual endogenous baseline FVIII plasma concentrations 9 -2816.1
Covariates on CL (added to model 3)
4 Age 10 -2851.8
5 Age, blood group 11 -2862.3
6 Age, blood group, bleeding complication 12 -2886.7
7 Age, blood group, bleeding complication, severity of surgical procedure 13 -2895.2
Covariates on V1 (added to model 7)
8 Age 14 -2911.8
Error model (added to model 8)
9 Center (two categories) 16 -2930.6
*Allometric scaling based on body weight was applied with an allometric exponent of 0.75 for the clearance parameters and 1 for the volume terms; under prediction of FVIII
plasma concentrations of a B-domain deleted product was implemented. NOP: number of estimated parameters; OFV: objective function value; IIV: inter-individual variability; V1:
volume of the central compartment; CL: clearance. 
The random parameters inter-individual variability (IIV) and
inter-occasion variability (IOV) of the PK parameters were esti-
mated using an exponential function according to:
 𝐶𝐿𝑖 = 𝜃𝐶𝐿 ×𝑒(𝜂𝑖+𝜅𝑖) 
where ηi and ki represent the IIV and IOV, respectively, and are
assumed to be symmetrically distributed with a mean of 0 and an
estimated variance of ω2 and p2. IIV and IOV were included in the
model if shrinkage was less than 20%.25 The structural model also
accounted for under prediction of plasma concentrations of a B-
domain deleted product (Refacto®) due to known discrepancies
and influence of one-stage laboratory assays on plasma concentra-
tions,26,27 as described:
Cpred,bdp = Cpred x (1 – θbdp)
Where Cpred,bdp and Cpred are the predicted concentrations of
the B-domain deleted product (bdp) and other products, respective-
ly, and θ is the fractional decrease in concentration. Residual vari-
ability in FVIII concentration was described using a combined
error model. 
Covariate search
After obtaining the structural model individual empirical
Bayesian estimates were obtained for all PK parameters.
Correlations between these parameters and patients’ and surgical
A perioperative population pharmacokinetic model 
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Table 4. Parameter estimates for the final model and bootstrap analysis.
Structural model Final model Bootstrap analysis final model
Parameter Mean (%RSE) Mean (%RSE) Mean (%RSE)
Structural model 
1 - Clearance (CL; mL/h/68 kg) 190 (5) 150 (8) 160 (5)
2 - Volume of central compartment (V1; mL/68 kg) 3030 (3) 2810 (4) 2810 (3)
3 - Inter-compartmental clearance (Q; mL/h/68 kg) 170 (17) 160 (20) 170 (15)
4 - Volume of peripheral compartment (V2; mL/68 kg) 1930 (12) 1900 (11) 1890 (8)
B-domain deleted product 0.32 (11) 0.34 (13) 0.33 (10)
Covariate parameters
5 - CL – Age (change with increasing age) -0.17 (22) -0.16 (13)
6 - CL – Blood group O (% difference) 26 (7) 27 (22)
7 - CL – Major surgical procedure (% difference) -7 (6) -7 (34)
8 - V1 – Age (change with increasing age) -0.09 (28) -0.09 (18)
Inter-individual variability
Clearance (% CV) 45 (13) 37 (14) 36 (10)
Volume of central compartment (% CV) 29 (13) 27 (14) 26 (11)
Residual variability
Additive residual error (SD; IUml-1)
Center 1,2,3 0.15 (12) 0.14 (9)
Center 4,5 0.05 (28) 0.05 (20)
Proportional residual error (% CV)
Center 1,2,3 0.18 (15) 0.18 (9)
Center 4,5 0.23 (9) 0.23 (7)
RSE: relative standard error; CL: clearance V1: volume of central compartment; Q: inter-compartmental clearance; V2: volume of peripheral compartment; CV: coefficient of 
variation; SD: standard deviation.
Figure 2. Visualization of NONMEM analysis and out-
comes. Allometric scaling based on body weight was
applied with an allometric exponent of 0.75 for the clear-
ance parameters and 1 for the volume terms; age in years;
IIV: inter-individual variability. 
characteristics, and the use of concomitant medication were
explored graphically. All covariates were tested in a univariate
analysis. The most clinically relevant and statistically significant
covariate was retained in the model: a stepwise forward approach
was used to determine clinical and statistically significant covari-
ates with P<0.05. Backward elimination was performed to con-
firm that all included covariates in the final model were statistical-
ly significant with P<0.01. As the occurrence of a bleeding com-
plication could not be related to actual FVIII plasma concentra-
tions,9 occurrence of a bleeding complication was not included in
the final model. Moreover, only a limited difference in clearance
was observed between patients with and without a bleeding com-
plication (7%). Also, time dependent changes in clearance were
tested during the perioperative period. 
Final model and model evaluation
The stability and performance of the final model was checked
using an internal validation procedure via the bootstrap resampling
technique in which 1000 bootstrap datasets were generated by
random sampling with replacement.28 Visual predictive check
plots obtained after Monte Carlo simulations of the study popula-
tion were used to evaluate if the final model adequately described
observed data.29 
Results
Patients and treatment in the perioperative setting 
Our cohort consisted of 119 hemophilia A patients
H. Hazendonk et al.
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Figure 3. Graphical visualization of variability of the clearance and
covariates. Visualization of variability of the clearance. (A) As a func-
tion of blood group O versus blood group non O. (B) As a function of
severity of surgical procedure. 
A
B
Table 5. Model equations describing the perioperative population PK model.
CL CL (mL/h) = 150 x ((body weight / 68)0.75) x ((age / 40)-0.17) x (1.26blood group) x (0.93severity of surgical procedure) 
V1 V1 (mL) = 2810 x (body weight / 68) x ((age / 40)-0.09)
Q Q (ml/h) = 160 x ((body weight / 68)0.75)
V2 V2 (mL) = 1900 x (body weight / 68)
Body weight (kilograms); Age (years); blood group equals one in case of blood group O and zero in case of blood group non O; severity of surgical procedure equals one in case
of a major surgical procedure and zero in case of a minor surgical procedure.
Severity of surgical procedure
Blood group O Blood group non  O
major major minor minor
undergoing a total of 198 surgical procedures, as described
previously.9 Patients were treated for up to two weeks
after surgery according to the National Hemophilia
Consensus (Table 1).3 Treatment consisted of a pre-opera-
tive bolus infusion of approximately 50 IU kg-1 followed
by a treatment scheme with either bolus infusions or con-
tinuous infusion therapy based on a clearance rate of 
3-4 mL kg-1 hour-1. General characteristics of these included
patients are shown in Table 2. Seventy-five patients under-
went only one surgical procedure. Half of all patients had
blood group O (51%). In 3% of all surgical procedures a
severe bleeding complication occurred, defined as necessi-
ty of a red blood cell transfusion (RBCT) and/or necessity
of a second surgical intervention, which could not be relat-
ed to FVIII plasma concentrations. In total, 1389 FVIII
measurements were obtained, equally distributed on con-
secutive days in the perioperative setting (Figure 1).
Approximately 7 samples per patient were taken in the
perioperative period. In summary, 45% of FVIII plasma
concentrations were below the target range in the first 24
hours and 75% were above the target range after six days
of hospitalization (Table 1).  
Pharmacokinetic modeling
Structural model development: time profiles of FVIII plasma
concentrations were best described by a two-compart-
ment model with allometric scaling for body weight
(Figure 2). By allometric scaling, all estimated PK parame-
ters were normalized for a body weight of 68 kg. Model
building steps that resulted in significant decrease of the
OFV, and consequently a better fit of the model, are
shown in Table 3. In the structural model, typical values
for CL and V1 were 190 mL/hour/68 kg and 3030 mL/68
kg (Table 4). It was possible to estimate IIV for CL and V1,
whereas estimates for IIV of Q and V2 were imprecise and
accompanied by a large shrinkage of more than 40%.25
Although this may suggest that there was no inter-patient
variability in Q and V2, this is due to the fact that the
available data were not sufficiently informative. The IIV
for CL and V1 were respectively 45% and 29%, underlin-
ing the importance of tailoring therapy to the individual.
Estimation of IOV on CL and V1 resulted in high shrink-
age values for both parameters (34% and 46%, respective-
ly); consequently IOV was not included in the model.
Inclusion of individual endogenous baseline FVIII plasma
concentrations and inclusion of a structural underpredic-
tion of plasma concentrations using a B-domain deleted
product improved the model. A proportional underpredic-
tion of 0.34 (34%) in FVIII plasma concentration was esti-
mated for this product. The residual error was described
using a combined error model. 
Covariate search: in the univariate analysis, significant
covariates of clearance were age (P<0.001), blood group
(P<0.01), severity of surgical procedure (P<0.01), lean
body mass (P<0.01), use of tranexamic acid and heparin
(P<0.05), historically measured VWF antigen and activity
levels (P<0.05). Treatment center and type of product
were not significant covariates. After the step forward
analysis, only age, blood group, and severity of surgical
procedure were significantly associated with clearance.
After the inclusion of age in the model, VWF antigen and
activity levels were no longer statistically significant. Age
was also associated with V1 (Table 3). Different models
were used to test possible time dependent changes in
clearance during the perioperative period; however, no
differences were observed. Differences in residual error
were detected for the different centers. 
In the final model, IIV of CL decreased from 45%
towards 37% after inclusion of these covariates. IIV of V1
decreased from 29% to 27%. The PK parameter estimates
of the final model are presented in Table 4. Typical PK
parameter estimates were described with the equations
presented in Table 5. 
According to the equation, clearance was 214, 169, 150
and 142 mL/h/68 kg for a typical patient (with blood
group non-O undergoing a minor surgical procedure) with
an age of 5, 20, 40 and 55 years, respectively. In case of a
major surgical procedure, a small decrease in CL was
observed of 7% (Table 4). Interestingly, individual post hoc
clearances were higher in patients with a major surgical
procedure (Figure 3B). This was, however, explained by
collinearity between covariates; older patients underwent
more major surgical procedures (Figure 4). Clearance
increased by 26% in patients with blood group O. CL and
elimination half-life are depicted as functions of age and
body weight in Figure 5. 
The adequacy of the derived final model is shown in
Figure 6. Population and individually predicted concentra-
tions for all patients were plotted against the measured
concentrations in Figure 6. A good agreement was
observed between FVIII concentrations predicted by the
model and those assessed by laboratory measurements.
Overall, standardized weighted residuals revealed a ran-
dom distribution around zero, within a range of  -2 to +2,
indicative of an unbiased estimation (Figure 6C).
Model evaluation: a good agreement was found between
parameter estimates of the final model and parameter esti-
mates of the bootstrap analysis (Table 4). A visual predic-
A perioperative population pharmacokinetic model 
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Figure 4. Clearance of FVIII in major and minor surgical procedures after strat-
ification for age. Post hoc estimates of FVIII clearance, normalized for total body
weight, and stratified for age (<4 years or >4 years) were categorized according
to severity of surgical procedure. *A Spearman’s correlation test was performed
to test for clearance differences between major and minor surgical procedures.
The median age of children included in the study was used as cut-off value for
analysis. This was supported by results of Figure 5A. 
tive check was conducted by 1000 simulations based on
the final model (Figure 1). It confirmed adequateness of
the model, as 7% of the measured concentrations were
calculated above the 95th percentile of the simulated con-
centrations and 9% of the measured concentrations were
found to be below the 5th percentile of the simulated con-
centrations. 
Discussion
In this study, a population PK model was constructed
describing the perioperative PK of several FVIII concen-
trates in current use. The majority of these factor VIII con-
centrates were FVIII recombinant products (77% of surgi-
cal procedures), of which 14% were a B-domain deleted
FVIII concentrate, as well as plasma-derived FVIII concen-
trates (23% of surgical procedures). In the population PK
model, a difference in results due to the B-domain deleted
FVIII concentrate (Refacto AF®) was accounted for. No
other differences were observed between products. As
this difference is incorporated into the population PK
model, this perioperative FVIII population PK model can
be used for all described FVIII concentrates. The devel-
oped model will facilitate Bayesian adaptive dosing,
allowing individualization of FVIII dosing during the
entire perioperative period. So far, only a few studies have
reported application of PK-guided dosing during the peri-
operative period. Unfortunately, in all these studies, only
the FVIII loading dose was based on an individual PK-pro-
file obtained several days before surgery.30-35 Iterative peri-
operative FVIII dosing-adjustments after first loading dose
could not be performed as there was no population PK
model. The perioperative population PK model presented
here will now make Bayesian adaptive dosing in this set-
ting possible. Moreover, it will consider all important
patients’ characteristics associated with clearance in the
surgical setting.
The model presented here consists of a two-compart-
ment model with allometric scaling of the PK parameters
according to body weight. Both increasing age and
increased severity of surgical procedure were overall sig-
nificantly associated with a lower FVIII clearance,
although individual clearance rates showed that patients
with a major surgical procedure did demonstrate higher
clearance rates. This contradiction may be due to the fact
that included covariates in the PK model were con-
founders, e.g. older patients with a decreased CL of FVIII
concentrate underwent major surgical procedures more
often than younger patients. Also, increased consumption
of concentrates due to blood loss and activation of coagu-
lation are other possible modifying factors. In addition,
blood group O was associated with higher FVIII clearance,
which will be discussed in the following sections.
Although it should be underlined that this population PK
model represents an important development, it is impor-
tant to realize that it does not account for pharmacody-
namic outcome measures, as the occurrence of a bleeding
complication could not be related to actual FVIII plasma
concentrations due to scarcity of FVIII plasma concentra-
tions during an acute bleeding event.
As in most resource rich countries, current perioperative
replacement therapy in hemophilia A in the Netherlands
consists of a FVIII loading dose followed by either contin-
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Figure 5. Clearance and elimination half-life as functions of age and body weight. (A) Clearance of FVIII, normalized for total body weight, as a function of age. (B)
Clearance of FVIII as a function of body weight. (C) The elimination half-life of FVIII as a function of age. (D) The elimination half-life of FVIII as a function of body
weight. Eta shrinkage was 10% and 20%, respectively, for the estimates of inter-individual variability of clearance and volume of the central compartment. 
A B
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uous FVIII infusion or treatment with FVIII bolus infusions
while targeting predefined peak and trough FVIII plasma
concentrations, as stated in the National Hemophilia
Consensus.3 The retrospective study performed to collect
data for this PK model has been described earlier.9 Results
show the challenges of current perioperative dosing of
FVIII replacement therapy in daily clinical practice when
targeting prescribed FVIII plasma concentrations, as signif-
icant underdosing and overdosing were demonstrated.
Moreover, it underlines the necessity of alternative more
individualized dosing strategies in the perioperative set-
ting; this is possible when PK-guided dosing based on a
population PK model is applied. 
PK-guided dosing based on population PK models has
mainly been studied in the long-term prophylactic setting.
However, in order to apply Bayesian adaptive dosing, it is
necessary to utilize a population PK model appropriate for
the individual patient and the specific setting concerned.
In analyses preceding the construction of this periopera-
tive population PK model, it was confirmed that the mean
estimated PK parameters for prophylactic dosing, as
reported by Björkman et al.,12 did not reliably predict
observed perioperative FVIII plasma concentrations. Using
the prophylactic model, calculations showed an underpre-
diction of perioperative FVIII concentrations of less than
1.00 IUml-1 as well as an overprediction of FVIII concentra-
tions of more than 1.00 IUml-1. In other words, actual FVIII
plasma concentrations were respectively higher and lower
than those predicted by a prophylactic population PK
model (data not shown). Therefore, it was concluded that
prophylactic population PK models can not be applied in
the perioperative setting. Use of the prophylactic model in
this setting would generate a bias of predicted periopera-
tive FVIII plasma concentrations. 
In the prophylactic setting, a similarly constructed pop-
ulation PK model has already been applied.12 CL, V1 and Q
were actually in accordance when a comparison was
made between perioperative and prophylactic PK popula-
tion model (CL: 150 vs. 222 mL/h/68 kg; V1: 2810 vs. 3520
mL/68 kg; and Q: 160 vs. 256 mL/h/68 kg, respectively).
However, in the present perioperative model, a value of
1880 mL/68 kg was found for V2 in contrast to a value of
240 mL/68 kg found in the prophylactic situation, suggest-
ing a rapid redistribution of FVIII concentrate following
intravenous administration.12 Due to increased V2, calcu-
lated distribution half-life and elimination half-life are sig-
nificantly larger (as half-life is a derivative of the distribu-
tion volume) in the perioperative setting in comparison
with the prophylactic state (4 hours and 25 hours vs. 0.6
hours and 12 hours, respectively). These calculated half-
lifes are in accordance with previously described half-life
observed immediately after surgery and half-life observed
at steady state of 10 surgical patients described with a sur-
gical model (9.6 and 17.8 hours, respectively) in compari-
son to 10 surgical patients described with an estimated
half-life of 10.1 hours described with a non-surgical
model.15 Unfortunately, the rapid redistribution was not
quantifiable, due to minimal data of laboratory assess-
ment after infusion. Previously, it has been suggested that
V2 may reflect the FVIII distribution into extravascular
spaces or within an intravascular compartment, more
specifically as a reflection of adhesion to the vessel wall, or
that it may reflect the process of a rapid initial
elimination.36,37 We hypothesized that an extra intravascu-
lar component resulting in a large V2 may be the result of
the high affinity and stoichiometry of FVIII to VWF,38 com-
bined with the significant increase of VWF after surgery
due to inflicted endothelial damage and its role in the
acute phase reaction.39 In addition, Deitcher et al. have
shown that volume of distribution increases after desmo-
pressin administration, which, of course, results in an
overall increase in VWF levels.40 
Moreover, we believe that VWF may play a crucial role
in the perioperative setting with regard to FVIII PK param-
eters, as previous studies have demonstrated a clear associ-
ation between VWF plasma concentrations and FVIII half-
life.41,42 This is not surprising, as VWF protects FVIII against
proteolytic degradation by expression of ABH antigens on
N-linked glycans and the uptake of the copper-binding pro-
tein ceruloplasmin.43,44 In addition, it has been shown that,
in healthy individuals undergoing orthopedic surgery, VWF
A perioperative population pharmacokinetic model 




Figure 6. Observed and model-predicted FVIII plasma concentrations. NON-
MEM model diagnostic plots, observed and model predicted FVIII plasma con-
centrations plotted against each other. (A) Population predicted FVIII plasma
concentrations. (B) Individually predicted FVIII plasma concentrations. (C)
Conditionally weighted residuals versus time.
decreases significantly intraoperatively and rises immedi-
ately after surgery.39 Therefore, we suspected a time-depen-
dent FVIII clearance in the presented PK model, with an
increased clearance during the surgical procedure itself and
a decrease in clearance directly after surgery. However, no
time-dependent clearance could be established.
Unfortunately, it was not possible to investigate the role of
VWF plasma concentrations in our analyses in more detail,
as VWF measurements are currently not routine practice in
the perioperative setting and only historically measured
VWF plasma concentrations were available in half of the
study population. However, a 26% higher clearance rate
was observed in blood group O patients in the periopera-
tive setting, underlining the potential importance of meas-
urement of VWF plasma concentrations in the periopera-
tive setting if PK-guided dosing is implemented. This is
supported by earlier reports that blood group O patients
have around 25% lower VWF levels in comparison to
patients with blood group non-O.43 Strikingly, this effect of
blood group on clearance was not significant in the pro-
phylactic population PK model as shown by Björkman et
al.12 However, we are not informed if VWF levels were
available for those analyses. In contrast, higher VWF levels
may also help explain the unexpected overall lower clear-
ance found in patients undergoing major surgical proce-
dures. The ongoing prospective randomized controlled
“OPTI-CLOT” trial (RCT) (described in more detail else-
where)45 will provide, among other things, an insight into
the pathophysiology of VWF in hemophilia patients during
the perioperative setting, and the relationship between
VWF levels and estimates of FVIII PK parameters. These
data will further validate the perioperative PK population
model presented here, refining its applicability, and further
defining the influence of possible modifying factors of PK
parameters. Moreover, extending this population PK
model, in combination with extended half-life (EHL) prod-
ucts in the near future could be of great value. However,
first of all, studies are needed to document in detail associ-
ations between clearance of current FVIII products and
EHL products within individuals. 
Clinically, in the perioperative setting, adaptive
Bayesian dosing can be used to optimize and individual-
ize dosing in order to obtain desired target FVIII plasma
concentrations with increased certainty. Bayesian analysis
combines individual PK data with information from an
available population PK model. Such a population PK
model is constructed from PK data of many individuals,
and not only embodies defined patients’ characteristics
known to influence clearance and other PK parameters,
but also as yet unidentified patients’ characteristics which
cannot be quantified. Individual patient information that
is entered into the model must include dose and time
point of factor concentrate administration, as well as the
FVIII plasma concentrations achieved. Incorporation of
the patient’s body weight, blood group, age and severity
of surgical procedure will improve estimation of the indi-
vidual clearance of factor concentrate. In clinical practice,
individual clearance and other PK parameter estimates
can be made by a clinical pharmacologist experienced in
this methodology and iteratively updated, leading to
calcu-lated dose adjustments. We are currently planning
to develop a PK tool to implement this perioperative pop-
ulation PK model in daily clinical practice. The first dose
of FVIII concentrate, still in steady state, will be based on
individual PK parameters deducted from an individual PK
profile constructed according to the prophylactic popula-
tion PK model. As we were not able to demonstrate time-
dependent changes in PK parameters during the perioper-
ative setting, the perioperative population PK model
described here can be applied to the complete periopera-
tive period with varying target FVIII plasma concentra-
tions, as described by National Guidelines.
In conclusion, we have constructed a perioperative pop-
ulation PK model facilitating iterative dose-adjustments by
Bayesian analysis. We believe this model will prove its
value as it will lead to optimization of current dosing
strategies by reducing underdosing and overdosing, and,
therefore, both a decrease of bleeding risk and an expected
overall reduction of factor concentrate consumption with
a subsequent reduction in costs. 
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